MESO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
Tagesvolumen	323 829
Durchschnittsvolumen	2.23M
Marktkapitalisierung	712.13M
EPS	$0 ( 2024-03-25 )
Nächstes Ertragsdatum	( $0 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.17
ATR14	$0.0140 (0.22%)

Volumen Korrelation

Lang: -0.01 (neutral)

Kurz: 0.95 (very strong)

Signal:(58.149) Expect same movement, but be aware

Mesoblast Limited Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Mesoblast Limited Korrelation - Währung/Rohstoff

-0.17
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.51
( weak negative )

Mesoblast Limited Finanzdaten

Annual	2023
Umsatz:	$7.50M
Bruttogewinn:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2023
Umsatz:	$7.50M
Bruttogewinn:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2022
Umsatz:	$10.21M
Bruttogewinn:	$-20.55M (-201.21 %)
EPS:	$-1.330

FY	2021
Umsatz:	$7.46M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.817

Financial Reports:

No articles found.

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.